IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes

[en] Background: Interferon lambdas (IFNLs) have important anti-viral/bacterial and immunomodulatory functions in the respiratory tract. How do IFNLs impact COPD and its exacerbations? Methods: Five hundred twenty eight patients were recruited in a prospective observational multicentre cohort (PROMISE) study. The genetic polymorphisms (rs8099917 and rs12979860) within the IFNL3/4 gene region and circulating levels of IFNL3 in COPD patients were determined and associated with disease activity and outcome during a median follow-up of 24 months. Results: The GG genotype significantly influenced severe exacerbation rate (42 vs. 23%; p = 0.032) and time to severe exacerbation (HR = 2.260; p = 0.012). Compared to the TT or TG genotypes, the GG genotype was associated with severe dyspnoea (modified medical research council score ≥ median 3; 22 vs 42%, p = 0.030). The CC genotype of the rs12979860 SNP was associated with a poorer prognosis (body mass index, airflow obstruction, dyspnea and exercise capacity index ≥ median 4; 46 vs. 36% TC vs. 20.5% TT; p = 0.031). Patients with stable COPD and at exacerbation had significantly lower circulating IFNL3 compared to healthy controls (p < 0.001 and p < 0.001, respectively). Circulating IFNL3 correlated to post-bronchodilator FEV1%predicted and the tissue maturation biomarker Pro-collagen 3. Conclusion: IFNL3/4 polymorphisms and circulating IFNL3 may be associated with disease activity and outcomes in COPD. © 2018 The Author(s).

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Egli, Adrian; University of Basel, Applied Microbiology Research, Department of Medicine, Basel, Switzerland, University Hospital Basel, Clinical Microbiology, Basel, Switzerland

Mandal, Jyotshna; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Schumann, Desiree M.; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Roth, Michael; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Thomas, Brad S.; University of Alberta, Li Ka Shing Institute for Virology, Edmonton, Canada

Lorne Tyrrell, D.; University of Alberta, Li Ka Shing Institute for Virology, Edmonton, Canada

Blasi, Francesco B.; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy

Kostikas, Konstantinos T.; University Hospital Basel, Clinic of Pneumology and Pulmonary Cell Research, Petersgraben 4, Basel, Switzerland

Boersma, Willem Germen; Department of Pneumology, Medisch Centrum Alkmaar, Alkmaar, Netherlands

Milenkovic, Branislava A.; Department of Pneumology, Institute for Pulmonary Diseases, Belgrade, Serbia

More authors (9 more)

Language :

English

Title :

IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes

Publication date :

21 March 2018

Journal title :

BMC Pulmonary Medicine

eISSN :

1471-2466

Publisher :

BioMed Central Ltd.

Volume :

Issue :

Pages :

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

SNSF PP00P3_128412/1); University of Basel “Nachwuchsförderung”; SNSF Ambizione, PZ00P3_154709/1

Funders :

SNSF - Swiss National Science Foundation [CH]
UNIBAS - Universität Basel [CH]

Available on ORBi :

since 12 October 2019

Statistics

Number of views

63 (6 by ULiège)

Number of downloads

49 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5:675-87.
McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87-103.
Egli A, Santer MD, O'Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Infect Dis. 2014:e51.
Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84:5670-7.
Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 2011;3:348-61.
Syedbasha M, Egli A. Interferon lambda: modulating immunity in infectious diseases. Front Immunol. 2017;8
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338-45. 1345 e1331-1337
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-9.
Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140:1021-31.
Egli A, Levin A, Santer DM, Joyce M, O'Shea D, Thomas B, Lisboa LF, Barakat K, Bhat R, Fischer KP, et al. Immunomodulatory function of interleukin-28B during primary infection with cytomegalovirus. J Infect Dis. 2014;
Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139:499-509.
Rallon NI, Soriano V, Naggie S, Restrepo C, McHutchison J, Vispo E, Benito JM. Impact of IL28B gene polymorphisms on interferon-lambda3 plasma levels during pegylated interferon-alpha/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother. 2012;67:1246-9.
Galani IE, Koltsida O, Andreakos E. Type III interferons (IFNs): emerging master regulators of immunity. In: Schoenberger SP, Katsikis PD, Pulendran B, editors. Crossroads between innate and adaptive immunity V. Volume 850: Springer; 2015.
Kling S, Donninger H, Williams Z, Vermeulen J, Weinberg E, Latiff K, Ghildyal R, Bardin P. Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy. 2005;35:672-8.
Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. Pediatr Infect Dis J. 2005;24:S217-22.
Steinke JW, Borish L. Immune responses in rhinovirus-induced asthma exacerbations. Curr Allergy Asthma Rep. 2016;16:78.
Kherad O, Kaiser L, Bridevaux P-O, Sarasin F, Thomas Y, Janssens J-P, Rutschmann OT. Upper-respiratory viral infection, biomarkers and COPD exacerbation. Chest. 2010;138:896-904.
Biancardi E, Fennell M, Rawlinson W, Thomas PS. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Intern Med J. 2016;46:1160-5.
Proud D, Chow C-W. Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2006;35:513-8.
Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012;10
Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12:1023-6.
Koch S, Finotto S. Role of interferon-lambda in allergic asthma. J Innate Immun. 2015;7:224-30.
Schwantes EA, Denlinger LC, Evans MD, Gern JE, Jarjour NN, Mathur SK. Severity of virus-induced asthma symptoms is inversely related to resolution IFN-lambda expression. J Allergy Clin Immunol. 2015;135:1656-9.
Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-STanca V, Edwards MR, Slater L, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183:734-42.
Mandal J, Roth M, Costa L, Boeck L, Rakic J, Scherr A, Tamm M, Stolz D. Vasoactive intestinal peptide for diagnosing exacerbation in chronic obstructive pulmonary disease. Respiration. 2015;90:357-68.
Boeck L, Mandal J, Costa L, Roth M, Tamm M, Stolz D. Longitudinal measurement of serum vascular endothelial growth factor in patients with chronic obstructive pulmonary disease. Respiration. 2015;90:97-104.
Boeck L, Soriano JB, Brusse-Keizer M, Blasi F, Kostikas K, Boersma W, Milenkovic B, Louis R, Lacoma A, Djamin R, et al. Prognostic assessment in COPD without lung function: the B-AE-D indices. Eur Respir J. 2016;47:1635-44.
Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, et al. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology. 2013;444:292-300.
Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, Jamnani FR, Fateh A, Siadat SD. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol. 2017;162:181-9.
Stolz D, Leeming DJ, Kristensen JH, Karsdal MA, Boersma W, Louis R, Milenkovic B, Kostikas K, Blasi F, Aerts J, et al. Systemic biomarkers of collagen and elastin turnover are associated with clinically relevant outcomes in COPD. Chest. 2017;151:47-59.
Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, Müller C, Struck J, Müller B, Tamm M. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058-67.
Hardy-Weinberg principle. https://en.wikipedia.org/wiki/Hardy%E2%80%93Weinberg_principle.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-4.
Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis. 2015;16:90-7.
Moran-Auth Y, Penna-Martinez M, Perner D, Susser S, Wicker S, Zeuzem S, Sarrazin C, Badenhoop K. IL28B gene variants and glucose metabolism in type 2 diabetes. Hum Immunol. 2016;77:1280-3.
Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011;55:1195-200.
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tmaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, et al. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2014;49:1152-62.
Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbanska A, Socha L, Boron-Kaczmarska A. IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retrovir. 2012;28:1640-6.
Arpaci D, Karakas CS, Can M, Cakmak GG, Kuzu F, Unal M, Bayraktaroglu T. Increased serum levels of IL-28 and IL-29 and the protective effect of IL28B rs8099917 polymorphism in patients with Hashimoto's thyroiditis. Immunol Investig. 2016;45:668-78.
Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011;54:859-65.
Alborzi A, Hashempour T, Moayedi J, Musavi Z, Pouladfar G, Merat S. Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. Med Microbiol Immunol. 2017;206:165-74.
Bullens DMA, Decraene A, Dilissen E, Meyts I, De Boeck K, Dupont LJ, Ceuppens JL. Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy. 2008;38:1459-67.
Nielsen MJ, Veidal SS, Karsdal MA, Orsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K. Plasma pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015;35:429-37.
Sand JMB, Knox AJ, Lange P, Sun S, Kristensen JH, Leeming DJ, Karsdal MA, Bolton CE, Johnson SR. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res. 2015;16